Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-19T08:42:03.862Z Has data issue: false hasContentIssue false

Efficacy of Immunization with a Combination of Serum and Recombinant Hepatitis B Vaccines

Published online by Cambridge University Press:  21 June 2016

Karlyn K. Pearl*
Affiliation:
William Beaumont Army Medical Center, El Paso, Texas
Ana A. Ortiz
Affiliation:
William Beaumont Army Medical Center, El Paso, Texas
William Pearl
Affiliation:
William Beaumont Army Medical Center, El Paso, Texas
*
Chief of Epidemiology and Disease Control, Preventive Medicine Service, William Beaumont Army Medical Center, El Paso, TX 79920

Abstract

Objective:

To evaluate the efficacy of giving a third dose of recombinant hepatitis B vaccine to healthcare workers who already had received two doses of serum-derived vaccine, which is no longer available in the United States.

Design:

Volunteers who already had received two standard doses of serum-derived vaccine were given a third dose of either serum or recombinant vaccine in a double-blind fashion. Antibodies to hepatitis B surface antigen were measured at the time of the third immunization, three months later, and one year after the third immunization.

Setting:

U.S. Army Medical Center, El Paso, Texas.

Patients:

One hundred healthy healthcare workers.

Results:

Three months after receiving the third immunization, the serum vaccine group had significantly higher titers than the recombinant vaccine group (P= 0.018). One year after receiving the third immunization, those who received the combined regimen had a mean hepatitis B surface antibody titer less than half that of those who received three doses of serum-derived vaccine. However, both regimens resulted in titers that are considered to confer immunity.

Conclusions:

A regimen that combines serum and recombinant hepatitis B vaccines may not produce as high an antibody level as three doses of the same vaccine. Those who began immunization with serum vaccine and concluded with recombinant vaccine should be monitored for an accelerated drop in serum antibodies.

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. U.S. Department of Health and Human Services. Recommendations for protection against viral hepatitis. MMWR 1985;34:313335.Google Scholar
2. Blumberg, BS. Background and perspective. In: Chisari, FV, ed. Advances in Hepatitis Research. Chicago, IL: Year Book Medical Publishers; 1984:18.Google Scholar
3. Francis, DP, Feorino, PM, McDougal, S, et al. The safety of the hepatitis B vaccine. JAMA 1986;256:869872.CrossRefGoogle ScholarPubMed
4. American Academy of Pediatrics. Report of the Committee on Infectious Diseases. 22nd ed. Elk Grove Village, IL American Academy of Pediatrics; 1991:238255.Google Scholar
5. Committee on Infectious Diseases, American Academy of Pediatrics. Universal hepatitis B immunization. Pediatrics 1992;89:795799.CrossRefGoogle Scholar
6. Hollinger, FB. Hepatitis B vaccines-to switch or not to switch. JAMA 1987;257:26342636.CrossRefGoogle Scholar
7. Byran, JP, Sjogren, M, Iqbal, M, et al. Comparative trial of low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccines. J Infect Dis 1990;162:789793.CrossRefGoogle Scholar
8. Merck, Sharp, and Dohme. Hepatitis B. West Point, PA Merck, Sharp, and Dohme; 1989.Google Scholar
9. Weissman, JY, Tsuchiyose, MM, Tong, MJ, et al. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988;260:17341738.CrossRefGoogle Scholar
10. Benenson, AS, ed. Control of Communicable Diseases in Man. 15th ed. Washington, DC: American Public Health Association; 1990.Google Scholar